Edition:
United States

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

250.30CHF
16 Nov 2018
Change (% chg)

-- (--)
Prev Close
CHF250.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,505,009
52-wk High
CHF252.85
52-wk Low
CHF206.35

Chart for

About

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas:... (more)

Overall

Beta: 0.98
Market Cap(Mil.): CHF216,341.70
Shares Outstanding(Mil.): 862.56
Dividend: 8.30
Yield (%): 3.30

Financials

  ROG.S Industry Sector
P/E (TTM): 20.67 28.12 29.34
EPS (TTM): 12.18 -- --
ROI: 21.29 14.10 13.58
ROE: 41.72 15.67 15.11

Drug developer Tesaro explores sale: Bloomberg

Cancer drug developer Tesaro Inc is exploring a sale and is working with financial advisers after receiving takeover interest, Bloomberg reported on Friday, citing people familiar with the matter.

Nov 16 2018

Drug developer Tesaro explores sale - Bloomberg

Nov 16 Cancer drug developer Tesaro Inc is exploring a sale and is working with financial advisers after receiving takeover interest, Bloomberg reported on Friday, citing people familiar with the matter.

Nov 16 2018

AbbVie sees hit to Humira sales from European competition

U.S. drugmaker AbbVie Inc on Friday lowered its forecast for overseas sales of its top-selling medicine, Humira, due to larger-than-expected pricing cuts because of new competition in Europe.

Nov 02 2018

CORRECTED-UPDATE 2-AbbVie sees hit to Humira sales from European competition

Nov 2 U.S. drugmaker AbbVie Inc on Friday lowered its overseas sales forecast for its top-selling medicine, Humira, as it agreed to larger-than-expected price cuts due to new European competition.

Nov 02 2018

AbbVie lifts profit target after cancer drug powers third-quarter beat

Nov 2 AbbVie Inc beat Wall Street estimates for third-quarter profit and raised its earnings forecast for the year on Friday, driven by strong sales of blockbuster cancer medicine Imbruvica.

Nov 02 2018

AbbVie, Roche combo treatment meets main goal of leukemia trial

(This Oct 31 story corrects paragraph one to say targeted therapy, not immunotherapy)

Nov 01 2018

CORRECTED-AbbVie, Roche combo treatment meets main goal of leukemia trial

Oct 31 AbbVie Inc and Roche Holding AG said on Wednesday their targeted therapy delayed the progression of a type of blood and bone marrow cancer when used in combination with the Swiss drugmaker's cancer drug in a late-stage trial.

Nov 01 2018

Swiss stocks - Factors to watch on Nov. 1

ZURICH/BERLIN, Nov 1 The Swiss blue-chip SMI was seen opening down 0.4 percent down at 8,990 points on Thursday, according to premarket indications by bank Julius Baer.

Nov 01 2018

BRIEF-Roche Announces EU Approval Of Venclyxto Plus Mabthera

* ROCHE ANNOUNCES EU APPROVAL OF VENCLYXTO PLUS MABTHERA FOR PEOPLE WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKAEMIA

Nov 01 2018

BRIEF-Roche Holding AG - Randomized Phase III CLL14 Study Met Its Primary Endpoint

* PHASE III DATA SHOWED THAT VENCLEXTA PLUS GAZYVA REDUCED THE RISK OF DISEASE WORSENING OR DEATH IN PEOPLE WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA WITH CO-MORBIDITIES

Oct 31 2018

Earnings vs. Estimates